Niacin USP by PureBulk.com — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

The safety score is low because the 500mg dose of Niacin is more than 14 times the recommended maximum daily limit of 35mg.

Label Data

100 mg Serving Size

500 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

500 mg (2500% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 500mg UL 35mg

Other Ingredients

None

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take 100 mg (scant 1/16 tsp) to 500 mg (scant 1/4 tsp) daily with meals, or as directed by physician.

⚠️ Warnings & Precautions

Check with your health professional before use.

Warning: This product is not intended for use by those with a serious medical condition or pregnant or lactating women.

Consult your physician before use.

Keep out of reach of children.

🧪 Formulation Notes

Free of: Sugar, soy, dairy, yeast, gluten, corn and additives.

Additional Information

Storage: Keep dry, cool & dark

US Standard Measuring Spoons Spoon Size (level) milligrams 1/16 teaspoon 136 1/8 teaspoon 273 1/4 teaspoon 547

Product Details

DSLD Entry Date 2013-06-25

Product Type Vitamin

Form Powder

Brand PureBulk.com

DSLD ID 23179

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →